BOEHRINGER Ingelheim has
combined Spiriva (tiotropium
bromide 5mg) with the new
Respimat Soft Mist Inhaler, with
the product to be added to the PBS
effective from tomorrow for the
treatment of COPD.
Spiriva Handihaler, which
is currently the most widely
prescribed COPD maintenance
therapy, will also continue to be
available in Australia.
BI also confirmed that it plans to
make several medications available
via the Respimat device, which uses
mechanical energy rather than a
propellant to deliver medication to
the airways as a slow moving fine
mist which helps maximise lung
deposition.
To view a video on the operation
of the Respimat inhaler see
pharmacydaily.com.au/videos.The above article was sent to subscribers in Pharmacy Daily's issue from 30 Sep 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Sep 15
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.